Evaluate to Launch World Preview 2013 Edition at Drug Information
Association (DIA) Annual Meeting
LONDON and BOSTON, June 13, 2013 /CNW/ - Patent expirations in 2012 have
put the industry through an unprecedented decline in worldwide
prescription drug sales in 2012. Now that the pharmaceutical industry
has faced the biggest patent cliff it has ever seen, Evaluate Ltd. will
examine its effects and what the industry can expect through 2018 in
its upcoming annual World Preview report. Evaluate will release the
report, which is based on EvaluatePharma® data, on Monday, June 24 in conjunction with the DIA 2013 49th Annual Meeting in Boston, MA.
The EvaluatePharma World Preview 2013 Edition will include:
Worldwide prescription and generic drug sales through 2018
Sales at risk due to patent expirations through 2018
Sales by therapy area through 2018
Global pharmaceutical R&D spend
FDA new drug approval analysis
Top grossing companies and products by market
M&A and venture funding analysis
For more information on the 2013 Edition of the World Preview report and
to receive your complimentary copy of the Executive Summary, please
visit the Evaluate booth #630 at DIA. The summary and full report will
be available on the Evaluate web site beginning June 24, 2013. Follow @evaluatepharma on Twitter for a reminder.
If you are attending the 2013 DIA Annual Meeting or the EphMRA 2013 conference and would like to meet, please Contact Us.
About Evaluate Ltd.
Established in 1996, Evaluate Ltd. is the leader in high quality life
science sector analysis. EvaluatePharma delivers exclusive consensus forecasts and trusted commercial insight
into biotech and pharmaceutical performance. EvaluateMedTech sets a new standard in integrated analysis and consensus forecasts of
the global medical device and diagnostic industry. EvaluateClinical Trials delivers unique intelligence to efficiently and accurately analyze the
global clinical trial landscape. A team of over 85 dedicated healthcare
analysts employ rigorous methodologies to collate, organize and deliver
the most-up-to-date commercial performance data available. An award
winning editorial team of journalists writing under the EP Vantage name
support EvaluatePharma's analysis. The Evaluate services enable the
life science community to make sound business decisions about value and
opportunity. For more information please visit http://www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.
SOURCE: Evaluate Ltd.
For further information:
Evaluate and EP Vantage
Chempetitive Group (for US media)
College Hill (for non-US media)
Melanie Toyne Sewell / Stephanie Bacher / Gemma Howe